Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDIS® (Telmisartan 80 mg p.o. Once Daily) and Diovan® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Hypertension After Missing One Dose
Sponsor: Bayer
A PHASE4 clinical study on Hypertension, this trial is completed. The trial is conducted by Bayer and has accumulated 7 data snapshots since 2001. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Mar 2026 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Oct 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Boehringer Ingelheim
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .